Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

CHARISMA Investigators; Peter B Berger; Deepak L Bhatt; Valentin Fuster; P Gabriel Steg; Keith A A Fox; Mingyuan Shao; Danielle M Brennan; Werner Hacke; Gilles Montalescot; Steven R Steinhubl; Eric J Topol

doi:10.1161/CIRCULATIONAHA.109.895342

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

CHARISMA Investigators, Peter B Berger, Deepak L Bhatt, Valentin Fuster, P Gabriel Steg, Keith A A Fox, Mingyuan Shao, Danielle M Brennan, Werner Hacke, Gilles Montalescot, Steven R Steinhubl, Eric J Topol

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

Uncertainty exists about the frequency, correlates, and clinical significance of bleeding with dual antiplatelet therapy (DAPT), particularly over an extended period in a stable population. We sought to determine the frequency and time course of bleeding with DAPT in patients with established vascular disease or risk factors only; identify correlates of bleeding; and determine whether bleeding is associated with mortality.

Original language	English
Pages (from-to)	2575-83
Number of pages	9
Journal	Circulation
Volume	121
Issue number	23
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.109.895342
Publication status	Published - 2010

Access to Document

10.1161/CIRCULATIONAHA.109.895342

Fingerprint

Dive into the research topics of 'Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial'. Together they form a unique fingerprint.

Cite this

CHARISMA Investigators, Berger, P. B., Bhatt, D. L., Fuster, V., Steg, P. G., Fox, K. A. A., Shao, M., Brennan, D. M., Hacke, W., Montalescot, G., Steinhubl, S. R., & Topol, E. J. (2010). Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation, 121(23), 2575-83. https://doi.org/10.1161/CIRCULATIONAHA.109.895342

CHARISMA Investigators ; Berger, Peter B ; Bhatt, Deepak L et al. / Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease : results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. In: Circulation. 2010 ; Vol. 121, No. 23. pp. 2575-83.

@article{99a425df4e644438a773fc0a240b6185,

title = "Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial",

abstract = "Uncertainty exists about the frequency, correlates, and clinical significance of bleeding with dual antiplatelet therapy (DAPT), particularly over an extended period in a stable population. We sought to determine the frequency and time course of bleeding with DAPT in patients with established vascular disease or risk factors only; identify correlates of bleeding; and determine whether bleeding is associated with mortality.",

author = "{CHARISMA Investigators} and Berger, {Peter B} and Bhatt, {Deepak L} and Valentin Fuster and Steg, {P Gabriel} and Fox, {Keith A A} and Mingyuan Shao and Brennan, {Danielle M} and Werner Hacke and Gilles Montalescot and Steinhubl, {Steven R} and Topol, {Eric J}",

year = "2010",

doi = "10.1161/CIRCULATIONAHA.109.895342",

language = "English",

volume = "121",

pages = "2575--83",

journal = "Circulation",

issn = "1524-4539",

publisher = "AMER HEART ASSOC",

number = "23",

}

CHARISMA Investigators, Berger, PB, Bhatt, DL, Fuster, V, Steg, PG, Fox, KAA, Shao, M, Brennan, DM, Hacke, W, Montalescot, G, Steinhubl, SR & Topol, EJ 2010, 'Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial', Circulation, vol. 121, no. 23, pp. 2575-83. https://doi.org/10.1161/CIRCULATIONAHA.109.895342

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. / CHARISMA Investigators; Berger, Peter B; Bhatt, Deepak L et al.
In: Circulation, Vol. 121, No. 23, 2010, p. 2575-83.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease

T2 - results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

AU - CHARISMA Investigators

AU - Berger, Peter B

AU - Bhatt, Deepak L

AU - Fuster, Valentin

AU - Steg, P Gabriel

AU - Fox, Keith A A

AU - Shao, Mingyuan

AU - Brennan, Danielle M

AU - Hacke, Werner

AU - Montalescot, Gilles

AU - Steinhubl, Steven R

AU - Topol, Eric J

PY - 2010

Y1 - 2010

N2 - Uncertainty exists about the frequency, correlates, and clinical significance of bleeding with dual antiplatelet therapy (DAPT), particularly over an extended period in a stable population. We sought to determine the frequency and time course of bleeding with DAPT in patients with established vascular disease or risk factors only; identify correlates of bleeding; and determine whether bleeding is associated with mortality.

AB - Uncertainty exists about the frequency, correlates, and clinical significance of bleeding with dual antiplatelet therapy (DAPT), particularly over an extended period in a stable population. We sought to determine the frequency and time course of bleeding with DAPT in patients with established vascular disease or risk factors only; identify correlates of bleeding; and determine whether bleeding is associated with mortality.

UR - http://www.scopus.com/inward/record.url?scp=77953806506&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.109.895342

DO - 10.1161/CIRCULATIONAHA.109.895342

M3 - Article

C2 - 20516378

SN - 1524-4539

VL - 121

SP - 2575

EP - 2583

JO - Circulation

JF - Circulation

IS - 23

ER -

CHARISMA Investigators, Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KAA et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation. 2010;121(23):2575-83. doi: 10.1161/CIRCULATIONAHA.109.895342

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

Abstract / Description of output

Access to Document

Other files and links

Fingerprint

Cite this